Evidence accumulating in support of cancer vaccines combined with chemotherapy: A pragmatic review of past and present efforts

International Journal of Oncology

Volumn 29, Issue 4, 2006, Pages 765-777

  Sinkovics, Joseph G ^a   Horvath, Joseph C ^b  

^a ST JOSEPH HOSPITAL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; FasL FasR autocrine growth circuits; Immunotherapy; Viral oncolysate cancer vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE;

ACTIVE IMMUNIZATION; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 33847197174     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.4.765     Document Type: Review

References (90)

1. Russ M: Questioning conventional oncology. An interview with cancer activist. Ralph W. Moss, PhD. Altern Complement Ther 7: 21-26, 2001.
2. Moss RW: The grand illusion of chemotherapy. Deutsche Zeitschr Onkol 33: 15-18, 2001.
3. Schirrmacher V: Antitumor immune memory and its activation for control of residual tumor cells and improvement of patient survival. A new concept derived from translational research with the virus-modified tumor vaccine ATV-NDV. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp481-531, 2005.
4. Sinkovics JG, Györkey F, Kusyk C and Siciliano MJ: Growth of human tumor cells in established cultures. Methods Cancer Res XIV: 243-323, 1978.
5. Sinkovics JG: Viral oncolysates as human tumor vaccines. Int Rev Immunol 7: 259-287, 1991.
6. Lindenmann J and Klein PA: Immunological aspects of viral oncolysis. Springer Verlag, New York, pp1-84, 1967.
7. Sinkovics JG: Progressive development of viral therapy of human cancers. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp1-147, 2005.
8. Gröschel D, Sinkovics JG and Rodriguez V: Project CP/cp2: the limulus test for detection of endotoxin in Gram-negative sepsis in cancer patients. Research Report 1974-1976. The University of Texas Cancer Center M.D. Anderson Hospital, Houston. University of Texas Press, Austin, pp221-225, 1976.
9. Sinkovics JG: Project M27/gm 15. Immunotherapy of cancer by immunization with cultured tumor cells. In: Research Report (Sept 1975-Aug 1977). The University of Texas M.D. Anderson Hospital and Tumor Institute, Houston. University of Texas Press, Austin, pp330-331, 1978.
10. Sinkovics JG, Plager C, McMurtrey MJ, Papadopoulos NE, Combs S, Romero JJ and Romsdahl MM: Adjuvant chemotherapy for malignant melanoma. In: Neoplasm Immunity Experimental and Clinical. Crispen RG (ed). Elsevier North-Holland, New York, Amsterdam, pp481-519, 1980.
11. Sinkovics JG, Plager C and McMurtrey MJ: Chemoimmunotherapy: basic principles and clinical examples. In: Basis for Cancer Therapy 2. Advances in Medical Oncology, Research and Education. Moore M (ed). Proc 12th Int Cancer Congress, Buenos Aires, Argentina. Pergamon Press, Oxford, New York, pp121-129, 1979.
12. Sinkovics JG, Papadopoulos N and Plager C: Viral oncolysates for the immunotherapy of human tumors. In: Advances in Comparative Leukemia Research 1981. Yohn DS and Blakeslee JR (eds). Elsevier BioMedical, New York, Amsterdam, pp613-615, 1982.
13. Sinkovics JG: Complete remissions lasting over three years in adult patients treated for metastatic sarcoma. In: Tumor Progression. Crispen RG (ed). Elsevier North-Holland, New York, Amsterdam, pp315-331, 1980.
14. Sinkovics JG, Thota H, Loh KK, Gonzalez F, Campos LT, Romero JJ, Kay HD and King D: Prospectives for immunotherapy for human sarcomas. In: Cancer Chemotherapy Fundamental Concepts and Recent Advances. 19th Annual Clinical Conference, The University of Texas M.D. Anderson Hospital, Houston, Year Book Medical Publisher, Chicago, pp417-443, 1975.
15. Sinkovics JG: Immunotherapy with viral oncolysates for sarcoma. JAMA 237: 869, 1977.
16. Sinkovics JG, Plager C and Romero J: Immunology and immunotherapy of patients with sarcomas. In: Neoplasm Immunity: Solid Tumor Therapy. Crispen RG (ed). Franklin Institute Press, Philadelphia, pp211-219, 1977.
17. Sinkovics JG, Campos LT, Kay HD, Loh KK, Gonzalez JR, Cabiness JR, Ervin F and Gyorkey F: Immunological studies with human sarcomas: effects of immunization and chemotherapy on cell- and antibody-mediated immune reactions. In: Immunological Aspects of Neoplasia. Williams & Wilkins, Baltimore, pp367-401, 1975.
18. Sinkovics JG: A reappraisal of cytotoxic lymphocytes in human tumor immunology. In: Cancer Biology and Therapeutics. The 1st H. Lee Moffitt Cancer Center Conference. Cory JG and Szentivanyi A (eds). Plenum Press, New York, London, pp225-253, 1986.
19. Sinkovics JG and Horvath JC: Human natural killer cells: a comprehensive review. Int J Oncol 27: 5-47, 2005.
20. Freedman RS, Edwards CL, Bowen JM, Lotzova E, Katz R, Lewis E, Atkinson N and Carsetti R: Viral oncolysates in patients with advanced ovarian cancers. Gynecol Oncol 29: 337-347, 1988.
21. Sinkovics JG, Cabiness JR and Shullenberger CC: Disappearance after chemotherapy of blocking serum factors as measured in vitro with lymphocytes cytotoxic to tumor cells. Cancer 30: 1428-1437, 1972.
22. Harris J, Sengar D, Stewart T and Hyslop D: The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37 (Suppl 2): 1058-1069, 1976.
23. Emens LA and Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65: 8059-8064, 2005.
24. Lake RA and Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405, 2005.
25. Coral S, Sigalotti M, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B and Maio M: 5-Aza-2-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 8: 2690-2695, 2002.
26. Demaria S, Volm M, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F and Symmans WF: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025-3033, 2001. (Pubitemid 32963819)
27. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K and Nishijima M: Mouse toll-like receptor 4MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol. J Biol Chem 275: 2251-2254, 2000. (Pubitemid 30081977)
28. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200: 297-306, 2004.
29. Sinkovics JG: Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL→FasR system. (erratum: as in the MS the FasR is CD95). Acta Microbiol Immunol Hungar 44: 295-306, 1997.
30. Sinkovics JG and Horvath JC: Virological and immunological connotations of apoptotic and anti-apoptotic forces in neoplasia. Int J Oncol 19: 473-488, 2001.
31. Yang S and Haluska F: Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin-granzyme and Fas-mediated pathways. J Immunol 172: 4599-4608, 2004.
32. Li W and Bertino J: Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. Mol Cancer Ther 14: 1343-1348, 2002.
33. Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190, 2005. (Pubitemid 41232299)
34. Gasser S and Raulet DH: The DNA damage response arouses the immune system. Cancer Res 66: 3959-3962, 2006.
35. + T cells. Nat Immunol 6: 593-599, 2005.
36. + T cells responding to self antigens. J Exp Med 196: 323-333, 2002.
37. Marzo AI, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW and Scott B: Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 162: 5838-5845, 1999. (Pubitemid 29314936)
38. Van der Most RG, Currie A, Robinson BW and Lake RA: Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66: 601-604, 2006. (Pubitemid 43165917)
39. Radvanyi LG, Banerjee A, Weir M and Messner H: Low levels of interferon-α induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 50: 499-509, 1999. (Pubitemid 29503456)
40. Prell RA, Li B, Lin JM, van Roey M and Jooss K: Administration of IFN-α enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 65: 2449-2456, 2005.
41. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, De Vecchis L, Turriziani M, Giorgi G, Bonmassar E and Francini G: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A*02.01 restricted CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 104: 437-445, 1993.
42. + tumors. Cancer Res 58: 4902-4908, 1998.
43. Byrd-Leifer C, Block E, Takeda K, Akira S and Ding A: The role of MydD88 and TLR4 in the LPS-mimetic activity of taxol. Eur J Immunol 31: 2448-2457, 2001.
44. Nowak A, Robinson B and Lake R: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358, 2002.
45. Machiels J-P, Reilly R, Emens I, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide, doxorubicin and paclitaxel enhance the anti-tumor immune response of GM-CSF-secreting whole cell vaccines in HER2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001.
46. Ercolini A, Machiels J-P, Chen YC, Slansky JE, Giedlen M, Reilly RT and Jaffee EM: Identification and characterization of the immunodominant rat HER2/neu MHC class I epitope presented by spontaneous mammary tumors from HER2/neu transgenic mice. J Immunol 170: 4273-4280, 2003. (Pubitemid 36428195)
47. Eralp Y, Wang X, Wang J, Maughan MF, Polo JM and Lachman LB: Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER2/neu in a mouse mammary carcinoma model. Breast Cancer Res 6: 275-283, 2004.
48. high T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030, 2000.
49. Nigan A, Ysacavone R, Zahurak M, Johns CM, Pardoll DM and Proietti E: Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Cancer 12: 161-170, 1998. (Pubitemid 28027242)
50. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB III, Mansour E, Haller DG, Manola J and Hanna MG Jr: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine. J Cin Oncol 18: 14-57, 2000.
51. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicalli D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J and Dahut W: A randomized phased I study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269, 2006.
52. Andersen MH, Østergard Pedersen L, Becker JC and Straten PT: Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61: 869-872, 2000.
53. + T lymphocytes. Clin Cancer Res 10: 828-839, 2004.
54. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen SW, Lee JH, Menander K, Chada DS and Gabrilovich DI: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878-887, 2006.
55. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D and Nadler LM: Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11: 4430-4446, 2005.
56. Stewart TH, Hollinshead AC, Harris JE, Belanger R, Crepeau A, Hooper GD, Sachs HJ, Klaassen DJ, Hirte W, Rapp E, Crook AF, Orizaga M, Sengar DP and Raman S: Immunochemotherapy of lung cancer. Ann NY Acad Sci 277: 436-466, 1976.
57. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM and Black KL: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847, 2001. (Pubitemid 32175145)
58. Wheeler CJ, Das A, Liu G, Yu JS and Black KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10: 5316-5326, 2004.
59. Lapis K and Tímár J: Role of elastin-matrix interactions in tumor progression. Semin Cancer Biol 12: 209-217, 2002.
60. Tímár J, Lapis K, Dudás J, Sebestyén A, Kopper L and Kovalszky I: Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12: 173-186, 2002.
61. Sinkovics JG: The predictive value of tissue culture and xenograft assays. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp320-396, 2005.
62. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zhou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
63. Shevach EM: Fatal attraction: tumors beckon regulatory T cells. Nat Med 10: 900-901, 2004.
64. Muller AJ and Prendergast GC: Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 65: 8065-8068, 2005.
65. Muller AJ, Duhadaway JB, Donover PS, Sutano-Ward E and Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319, 2004.
66. Belardelli F, Ferrantini M, Parmiani G, Schlom J and Garaci E: International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 64: 6827-6830, 2004.
67. Cassel WA, Murray DR and Olkowski ZL: Newcastle disease virus oncolysate in the management of stage III malignant melanoma. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp677-689, 2005.
68. Horvath JC: Newcastle disease virus: its oncolytic properties. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp533-574, 2005.
69. Sinkovics J: Die Grundlagen der Virusforschung. Budapest, Hungary: Verlag der ungarischen Akademie der Wissenschaften, Budapest, Hungary, pp3-420, 1956.
70. Sinkovics JG, Groves GF and Howe CD: Actions of interferon in tissue cultures harboring mouse leukemia virus. Experientia 24: 927-928, 1968.
71. Sinkovics JG and Howe CD: Superinfection of tumors with viruses. Experientia 25: 733-734, 1969.
72. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, Kennedy R, Errington F, Harrington KJ, Melcher A and Vile R: Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 62: 5495-5504, 2002.
73. Bateman A, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, Linardakis E, Riddle D, Dietz A, Lohse CM, Strome S, Peterson T, Simari R and Vile RG: Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigen by dendritic cells. Cancer Res 62: 6566-6578, 2002.
74. Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile R and Melcher A: Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12: 1333-1341, 2006. (Pubitemid 43342526)
75. Andersen MH, Gehl J, Reker S, Geertsen P, Becker JC and thor Stratem P: Concomitant adminstration of interleukin-2 during therapeutic vaccination against cancer: the good, the bad, or the evil. J Clin Oncol 23: 5265-5267, 2005.
76. Singluff CL, Chianese-Bullock K and Yamschikov G: Interleukin-2 effects deserve further study: a need for better understanding of biology and of optimal dose regimens. J Clin Oncol 23: 5267-5268, 2005. (Pubitemid 46224045)
77. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G and Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-711, 2006.
78. Sinkovics JG and Horvath JC: Virus therapy of human cancers. Melanoma Res 13: 431-432, 2003.
79. Sinkovics JG: Glioblastoma multiforme. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker, New York, pp410-425, 2005.
80. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Gelewtneky K, Ahmadi R, Schule-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V and Herold-Mende C: Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety and clinical benefit. J Clin Oncol 22: 4272-4281, 2004.
81. Rosenberg SA and Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Nat Acad Sci USA 101: 14639-14645, 2004.
82. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
83. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004. (Pubitemid 39273730)
84. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 20: 2665-2676, 2000.
85. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
86. Sinkovics JG: Interferons: antiangiogenesis agents. Can J Infect Dis 3 (Suppl): 128-132, 1992.
87. Terando A and Mulé JJ: On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 52: 680-685, 2003.
88. Goillot E, Combaret V, Ladenstein R, Baubet D, Blay JY, Philip T and Favrot MC: Tumor necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Res 52: 3194-3200, 1992.
89. Shinohara H, Yagita H, Ikawa Y and Oyaizu N: Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60: 1766-1772, 2000.
90. Sinkovics JG: On the threshold of the door of 'no admittance'. In: The Immunologic Revolution: Facts and Witnesses. Friedman H and Szentivanyi A (eds). CRC Press, Boca Raton, pp241-286, 1994.